

INTRODUCTION

Cervical cancer (CC) is the second leading cause of gynaecological cancer-related deaths worldwide [1]. RAIDS is a consortium composed of academic clinical centers and SME's from 7 European countries: France, Germany, Netherlands, Moldova, Romania, Serbia and Hungary with the objective to improve treatment strategies in this relatively rare disease in countries with both excellent screening techniques and well developed clinical research centres.



AIMS

Our aims are to evaluate carefully the needs and concerns of the patients in this multicultural background as well as to provide them with relevant information, specifically on new developments in precision medicine and in innovative treatment options based on the molecular analysis of their tumors.

MATERIAL & METHODS


In order “to hear the patients viewpoint” and to better understand patient concerns, we have created a Dropbox on the website of our project: {<http://www.raids-fp7.eu>}. Here patients, relatives and medical doctors can ask their questions in their native language. They will receive an answer from the most appropriate clinician/scientist participating in the RAIDS and BioRAIDS projects.

RAIDS project includes:

1. BioRAIDS, an important biobanking trial, through which we aim to identify predictive biomarkers for treatment response. The ultimate objective is to stratify the patients according to their molecular profiles for a better treatment strategies.
2. DNA vaccine trial, phase 1 on 12 VIN3 patients has been finished, analysis of safety and immunological response is ongoing.
3. Preclinical studies on cell lines and mouse models attempted to develop innovative treatment strategies. future development.

DROPBOX PRESENTATION

If you have any questions about cervical cancer : please visit RAIDS site www.raids-fp7.eu



If you have any questions concerning cervical cancer you can ask them here Your question, Votre question, ihre Fragen, Vaše pitanje, întrebarea dvs, uw vraag

Clinicians participating in RAIDS project will answer you. Answer, réponse, die antworten, odgovor, răspuns, antwoord



And get the answer on RAIDS site


The RAIDS project is ongoing until April 2017 after a 18 months prolongation. Please do not hesitate to contact us or to visit our website.

First questions are coming in. These questions concern the treatment strategies which can be used for the treatment of different stages of disease.

Clinicians from the respective countries provided a response and translated the question and the answer into English. These discussions can be viewed on the site as demonstrated above.

UPDATE ON RAIDS PROJECT

BioRAIDS – biobanking clinical study:



As of October 2015, 206 patients have been accrued in the clinical BioRAIDS protocol and sampling of their primary tumor as well as of blood/serum has been carried out.

Liquid biopsies: A blood test is planned every 6 months until Mo18 and will allow to define serum markers that shall help identify clearance or progression of the tumor in the future and should be better able to detect a recurrence at a very early stage.

Sequencing: Tumor and blood/serum samples are sent to the respective laboratories in batches and the molecular analyses of 80 patients’ samples are ongoing. Full exome analysis of the first 48 patients has already been carried out. Full exome sequencing will be performed on tumors containing more than 30% of tumor cells; samples with less than 30% of tumor cells will be used for targeted sequencing.

Bio informatics analysis is ongoing and early results on the first 30 patients pinpoint the relative frequency of mutational parameters some of which have been associated with outcome by other clinical studies.

Other investigations involving the role of the tumor micro environment, of the viral HPV type in the tumor, of activated protein pathways.

Preclinical investigations also explore strategies to modify the cells surrounding the tumor, such as to make treatment strategies more efficient. Cell line studies have already explored drugs that are of interest, but not commonly used in cervical cancer.

Finally **therapeutic vaccine strategies** are explored pre-clinically on mouse models and should hopefully find their way into the clinical trials unit in the not too distant future.

PERSPECTIVES

Our dropbox is meant to support individual patients and patients’ advocacy groups as well as to inform the larger community.

The RAIDS platform may serve to inform patients about on-going clinical trials in which they might participate (if eligible according to each trial inclusion and exclusion criteria) as well as on innovative preclinical work .

We are currently debating on how psychosocial aspects might best be addressed.

For this purpose we think to organize in the near future a “think tank” involving patient groups.

We shall also work in unison with ‘ENGAGE’ (European Network of Gynecological Cancer Advocacy Groups) under the auspices of ESGO to further explore patients’ needs.

ACKNOWLEDGEMENTS

The research leading to these results has received funding from the European Community’s Seventh Framework Program (FP7/2007-2013) under grant agreement n° 304810 - RAIDS

REFERENCES

1. RAIDS project – dropbox:<http://www.raids-fp7.eu/a-question.html>
2. ENGAGE http://engage.esgo.org/sites/default/files/atoms/files/cervical_cancer_fact_sheet_0.pdf

CONTACT INFORMATION

Suzy Scholl – Coordinator of RAIDS project
suzy.scholl@curie.fr

